# An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins

> **NCT00928421** · PHASE2 · COMPLETED · sponsor: **Boston Scientific Corporation** · enrollment: 16 (actual)

## Conditions studied

- Varicose Veins

## Interventions

- **DRUG:** Polidocanol Endovenous Microfoam 0.125%

## Key facts

- **NCT ID:** NCT00928421
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928421, "An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00928421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*